About this trial
The purpose of this trial is to generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft Systems verses Gore Excluder / Excluder Conformable AAA Endoprosthesis in subjects with Abdominal Aortic Aneurysms. Subjects are randomized and imaging collected at all follow-up time points to assess the primary endpoint.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Subject and the treating physician agree that the subject will return for all required follow up visits
Subject or legal representative or consultee, as applicable, has consented for trial participation and signed the Informed Consent approved by the sponsor and by the Ethics Committee/Institutional Review Board
Subject has an aneurysm diameter of ≥ 5 cm (if woman) ≥ 5.5 cm (if man) or as stated otherwise in regional addenda.
Subject's AAA anatomy is appropriate for both Medtronic Endurant II/IIs Stent Graft System and Gore Excluder/Excluder Conformable AAA Endoprosthesis as per assessment of both treating physician and Core Lab in accordance with the overlapping commercially available IFUs per applicable region.
Disqualifiers
Subject is participating in an investigational drug or device study which may bias or interfere with the endpoints and follow-up of this trial
Subject has an estimated life expectancy of ≤ 3 years as judged by the investigator
Suprarenal/pararenal/juxtarenal
Isolated ilio-femoral
Trial design
Parallel
Treatments tested in this trial
Medtronic Endurant II or Endurant IIs Stent Graft System
DeviceEVAR treatment with Medtronic Endurant II/IIs Stent Graft System
Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis
DeviceEVAR treatment with Excluder / Excluder Conformable Stent Graft System
Treatment groups
Trial outcomes
Primary outcomes
Sac Regression
Proportion of patients with sac regression at 1 year, defined in accordance with SVS guidelines as the reduction in maximum diameter by \>= 5 mm when compared to the first CT imaging study obtained within 90 days after index procedure.
Secondary outcomes
Aneurysm sac change by diameter as a continuous variable
Aneurysm sac change by volume incidence rate
Type II endoleak incidence rate
Type I endoleak incidence rate
Sponsors and contacts
Click on the lead sponsor to view all of their trials.